Nanjing King-friend Biochemical Pharmaceutical Co Ltd (603707.SS) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · China · ISIN CNE100002WP3
Nanjing King-friend Biochemical Pharmaceutical Co Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 3.92 bn CNY | 3.99 bn CNY |
| Gross profit | 1.81 bn CNY | 1.57 bn CNY |
| Operating income | 994.33 m CNY | 581.37 m CNY |
| EBIT | 963.27 m CNY | 754.67 m CNY |
| Net income | 826.14 m CNY | 581.54 m CNY |
| Diluted EPS – continuing operations | 0.50 CNY | 0.36 CNY |
Full history since 2013, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research, development, production, and sale of pharmaceutical raw materials and preparations in China and internationally. The company offers generics for oncology, critical care, IVF, and diabetes; and standard heparin preparations and low molecular weight heparin preparations, including enoxaparin sodium injections, dalteparin sodium injection, and nadroparin calcium injection. It also provides non-heparin sterile injections, such as adalimumine injection, paclitaxel injection, liraglutide injection, daptomycin for injection, pantoprazole sodium for injection, reganoxone injection, leucovorin calcium for injection, bivalirudin for injection, micafungin for injection, ducalciferol injection, fondaparinux sodium injection, and cisatracurium besylate injection. In addition, the company offers process development and preparation, process optimization, registration and validation approval, and manufacturing, as well as customized research and development, and manufacturing for commercialization. Its injection products are used in anticoagulation, anti-tumor, and cardiovascular disease areas, surgical anesthesia, antibacterial infection, and contrast imaging. The company was founded in 2000 and is based in Nanjing, China.
More stocks
- Chorus Ltd (CNU.AX)
- Xinhuanet Co Ltd (603888.SS)
- GORMAN RUPP CO (GRC)
- SMA Solar Technology (S92.DE)
- LEMAITRE VASCULAR INC (LMAT)
- Grand Pharmaceutical Group Ltd (512.HK)
- Robertet SA (RBT.PA)
- Zhejiang Kaishan Compressor (300257.SZ)
- Sineng Electric Co Ltd (300827.SZ)
- Guangzhou Kingmed Diagnostics Group Co Ltd (603882.SS)
- Burckhardt Compression Holding AG (BCHN.SW)
- Jiangsu Dingsheng New Material Joint-Stock Co Ltd (603876.SS)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.